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Abstract: Background: Bacterial infections are still one of the main factors associated with mortality 
worldwide. Many radiopharmaceuticals were developed for bacterial imaging, both with single 
photon emission computed tomography (SPECT) and positron emission tomography (PET) 
isotopes. This review focuses on PET radiopharmaceuticals, performing a systematic literature 
review of published studies between 2005 and 2018. Methods: A systematic review of published 
studies between 2005 and 2018 was performed. A team of reviewers independently screened for 
eligible studies. Because of differences between studies, we pooled the data where possible, 
otherwise, we described separately. Quality of evidence was assessed by Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS) approach. Results: Eligible papers included 35 published 
studies. Because of the heterogeneity of animal models and bacterial strains, we classified studies 
in relation to the type of bacterium: Gram-positive, Gram-negative, Gram-positive and negative, 
others. Conclusions: Results highlighted the availability of many promising PET 
radiopharmaceuticals for bacterial imaging, despite some bias related to animal selection and index 
test, but few have been translated to human subjects. Results showed a lack of standardized 
infection models and experimental settings. 
Keywords: PET; bacteria; nuclear medicine imaging; infection 
 
1. Introduction 
For several decades, nuclear medicine modalities like three-phase bone scintigraphy, 
67Ga-citrate scintigraphy, and radiolabeled white blood cell scintigraphy have been used for imaging 
infection and inflammation. In the last years, new techniques and new radiopharmaceuticals have 
been proposed such as 2-deoxy-2[18F]fluoro-D-glucose ([18F]FDG) [1,2] and many bacterial specific 
agents [3].  
Early in the history of clinical whole-body [18F]FDG-PET occasional reports of false positive 
findings due to inflammation in patients with malignant tumors were considered a nuisance caused 
by the non-specificity of [18F]FDG [4]. Tahara et al. were among the firsts to report specific [18F]FDG 
accumulation in abdominal abscesses [5]. It is now well-known that [18F]FDG is taken up by cells 
involved in the inflammatory response (e.g., neutrophils, macrophages and activated leukocytes) 
because they express high levels of glucose transporters like malignant cells (albeit not to the same 
extent), and in addition, circulating cytokines seem to increase the affinity of these glucose 
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transporters for [18F]FDG [6]. Moreover, [18F]FDG uptake has been shown to correlate very well with 
the inflamed tissue in both septic and aseptic inflammation [7,8] and it has recently been shown that 
some bacterial strain can also bind [18F]FDG [9].  
Nevertheless, the non-specificity is now considered an asset in some settings, e.g., fever of 
unknown origin, a heterogeneous group of diseases with a multitude of differential diagnoses of 
infectious, malignant, or inflammatory etiology most of which have an element of hypermetabolism. 
As a sensitive whole-body modality, [18F]FDG-PET/CT may guide the clinicians towards more 
specific investigations to secure an etiologic diagnosis, and many infectious and inflammatory 
diseases have a systemic component to merit [18F]FDG whole-body imaging [2].  
Nonetheless, the non-specific nature of [18F]FDG may also be a hindrance in other settings, as 
the distinction between aseptic inflammation and infectious foci is difficult. Much work has been 
invested in optimizing the use of [18F]FDG and much still lies ahead, e.g., better interpretation 
criteria, more elaborate quantitative techniques, and multiple-time-point imaging, which all have 
shown considerable promise in some settings [10,11]. However, just as tumour imaging has seen the 
introduction of several more specific PET-radiopharmaceuticals with alternative isotopes (e.g., 
prostate-specific membrane antigen (PSMA)-imaging for prostate cancer and various 
radiopharmaceuticals for neuroendocrine tumours), more specific radiopharmaceuticals are also 
being investigated for infection and inflammation. We have previously reviewed available 
radiopharmaceuticals for gamma camera imaging [3,12], but also for PET imaging, and a multitude 
of alternative candidates have been presented and assessed pre-clinically. Unfortunately, only few 
have been translated to humans with limited success.  
Early on, various broad-spectrum fluorine-18-based radiopharmaceuticals known from cancer 
imaging were explored, perhaps not surprising as they were readily available and because they 
aimed at for instance increased proliferation which also applies to bacteria, e.g., 
3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) in S. aureus, but results did not transcend the 
non-specificity of [18F]FDG [13–15]. Similarly, with the availability of gallium-68, a PET-equivalent of 
67Ga-citrate and other radiopharmaceuticals like [68Ga]gallium-UBI were developed and tested in 
animal models and humans. The use of gallium-68 has many advantages, including a favourable 
half-life of 68 min and generator availability, but despite promising results they were not 
convincingly better than [18F]FDG [16–18]. 
Other isotopes have been also tested, e.g., copper-64 (64Cu) bound to a peptide targeting a 
leucocyte receptor, but not directed specifically against a microorganism [19]. Finally, it is worth 
mentioning that white blood cells (WBC) labelling with [18F]FDG has being explored, but although 
initial studies were very promising, later results were more equivocal [20–23], thus techenetium-99m 
and indium-111-labelled WBC remain the gold standard technique for imaging infections [24]. 
Thus, in recent years, interest has turned towards more infection-specific radiopharmaceuticals, 
i.e., radiopharmaceuticals aimed directly at the microorganism and not only at the secondary 
inflammatory response [25]. The ability to directly diagnose specific microorganisms would be very 
attractive, especially in areas not readily accessible for sampling. In an attempt to qualify the 
discussion, we aimed to systematically survey and review the literature to evaluate the current 
status of the many potential candidates that have been presented.  
2. Materials and Methods 
2.1. Inclusion Criteria 
In the present review, only published articles that met the following criteria were included: 
articles (only original papers); radiopharmaceutical (any non-[18F]FDG-PET radiopharmaceutical); 
target (only specific for bacteria); experimental design (only in vivo targeting studies). Publications 
selected for this review were from peer-reviewed indexed journals. 
2.2. Exclusion Criteria 
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Reviews, case reports, abstracts, editorials, poster presentations, publications in languages 
other than English, studies regarding [18F]FDG, studies in which compounds were not essentially 
specific for bacteria, articles with only in vitro studies or technical data, were excluded. The decision 
to include or exclude an article was made by consensus. 
2.3. Search Methods for Identificationof Studies 
The selection of published articles was based on the PRISMA guidelines [26]. 
We selected all studies published in English language regardless of publication status 
(published, ahead of print, in press, etc.). The following algorithm was used: (PET AND bacteria*) 
OR (PET and infect*); filters: published in the last 10 years. We searched for published papers 
present in PubMed (last 10 years) and Scopus (2005–2018). The literature search was broadened to all 
reference lists of all retrieved. 
2.4. Data Extraction and Management 
All authors screened independently full-text manuscripts for eligibility, reporting essential data 
in a summary table. Risk assessment of any potential bias and data collection was performed by 
using a standardised questionnaire, adjusted to included studies. Any disagreement was resolved 
through discussion. 
2.5. Risk Assessment of Bias in Included Studies 
The included studies were evaluated by using the Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS) approach for any potential bias and variation [27]. We analysed the following 
variables: (1). animal selection bias (animal origin, animal model); (2). infection model bias 
(bacterium origin, bacterium number); (3). experimental design variation (infection model, 
radiopharmaceutical purity and specific activity); (4). reference standard bias (inappropriate 
reference standard, incorporation bias); (5). reference standard variation (definition of control 
model); (6). flow and timing bias (infection progression bias, radiopharmaceutical administration 
time, imaging time bias, uninterpretable test results, sample size). Each study was analyzed 
providing this information. Considering the heterogeneity of animal models and bacterial strains, 
we classified studies in relation to the type of bacterium (Gram-positive, Gram-negative, 
Gram-positive and negative, others). 
3. Results 
3.1. Data Synthesis  
Because of differences between studies (bacterial strain, infection model, isotope, compound, 
reference standard), data were pooled, when possible. When not, they were separately described. 
We found 69 potential studies that evaluated PET radiopharmaceuticals for bacterial imaging. After 
excluding the non-eligible articles, we analysed 35 published studies, shown in Figure 1. A summary 
of results is reported in Table 1, whereas a summary of QUADAS analysis is reported in Table 2. 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flowchart 
of included papers. 
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Table 1. Summary table of papers included in the systematic review. 
First author 
[ref] 
Pathogen Compound 
Radiolabeling 
Method 
Isotope 
Specific 
Activity  
Stability 
Model of 
Study 
Metabolic 
Route 
Amount 
(CFU) and 
Infection site 
Max 
Target-to-no
n Target 
(T/NT) Ratio 
Control 
Experiment 
Other Comments by Authors 
Bhatt J 
[28] 
S. aureus  UBI-31-38 
1,4,7-triazacycl
ononane-N,N',
N''-triacetic 
acid (NOTA) 
chelator 
68Ga 
2.1 × 106 
MBq/mmol 
both in 
saline 
and 
serum up 
to 2 h 
BALB/c 
mice 
kidneys 
107, right 
thigh 
3.24 ± 0.7 
107 heat 
killed, left 
thigh 
imaging in 2 
patients and 1 
negative 
control 
good localization of 
infection site, high T/NT 
ratio and promising results 
in humans 
Nielsen KM 
[29] 
S. aureus  
K-A9 
peptide 
1,4,7,10-Tetraaz
acyclododecane
-1,4,7,10-tetraac
etic acid 
(DOTA) 
chelator 
68Ga 
1.4 × 104 
MBq/mmol 
up to 2 h 
C57BL/6 
mice 
kidneys 5 × 107 1.89 ± 0.88 
turpentine 
oil 
comparison 
with 
2-deoxy-2[18F
]fluoro-D-glu
cose (FDG) 
no in vivo selectivity 
Mutch CA 
[30] 
E. coli  
Para-Amino
benzoic Acid 
(PABA) 
argon carrier 
gas 
11C 
820 ± 258 
mCi/μmol 
- 
 CBA/J 
mice 
kidneys 
108, left 
shoulder 
2.8 vs 1 
(region of 
interest) 
108 killed, 
right 
shoulder 
- 
attractive 
candidate for imaging 
living bacteria in humans. 
Takemiya K 
[31] 
S. aureus  
Maltohexaos
e (FHM) 
nucleophilic 
fluorination 
18F - - 
Sprague-
Dawley 
rats 
feces, urine 
2.9 × 108, 
stainless steel 
implant, back 
- 
turpentine 
oil 
negative 
controls 
comparison 
with FDG 
FHM is better than FDG in 
differentiating 
non-infection inflammation 
from infection 
Ebenhan T 
[32] 
only in vitro test, 
in vivo 
biodistribution 
in non-human 
primates (NHP) 
and humans 
UBI-29-41 NOTA chelator 68Ga 
13.8 ± 1.9 
GBq/mmol 
- 
vervet 
monkeys 
(NHPs) 
liver, 
kidneys 
- 
3.3 ± 0.3 
maximum 
standard 
uptake value 
(SUVmax) at 
1h 
- 
human 
studies (2 
healthy and 3 
patients) 
non-toxic, safe compound, 
identify infectious foci in 
humans; need further 
studies 
Li J 
[33] 
K. pneumoniae  
Sorbitol 
(FDS) 
nucleophilic 
fluorination 
18F - - 
C57BL/6 
mice 
kidneys 105 live, lungs 
8.5 (FDS) and 
1.7 (FDG) 
108 killed, 
lungs 
comparison 
with FDG 
FDS is better than FDG to 
detect lung infection from 
inflammation 
Pickett JE 
[34] 
Gram-positive 
SAC55 
(anti-LTA) 
Deferoxamine 
(DFO) chelator 
89Zr 
9.439–12.210 
(1.7–2.2 mCi/g) 
- 
C57BL/6 
mice 
- 
4.3 × 104, 
femur, 
inoculated 
implant 
- 
1.4 × 103, 
sterile 
implant 
comparison 
with FDG, 
NaF, 89Zr-IgG 
(control) 
potential differentiation 
between infection and 
sterile inflammation 
Sellmyer 
MA 
[35] 
E. coli and P. 
aeruginosa  
S. aureus  
trimethopri
m 
nucleophilic 
fluorination 
18F 
5–15 × 106 
mCi/mmol 
- 
BALB/c 
mice and 
NHP 
(rhesus 
monkey) 
kidneys, 
liver 
106 hindlimb, 
107 forelimb, 
108 ear pinna 
2.7 vs 1.3 vs 1 
(infection vs 
inflammation 
vs tumor) 
106, 107, 108 
killed, 
contralateral 
left 
comparison 
with 
inflammation 
and cancer 
performing 
specific for infection 
imaging 
J. Clin. Med. 2019, 8, 197 6 of 25 
 
(biodistri
bution) 
FDG too 
Gowrishan
kar G 
[36] 
Gram-positive 
Gram-negative 
maltotriose 
nucleophilic 
fluorination 
18F - - 
nude 
mice (E. 
coli), CD1 
mice (P. 
aeruginosa
, L. 
monocytog
enes), 
BALB/c 
mice 
(LPS) 
kidneys 
108 E. coli,  
106 P. 
aeruginosa, 2 × 
105 L. 
monocytogenes 
- 
Lipopolysac
charide 
(LPS) 
inflammatio
n, 106,7,8 heat 
killed E. coli 
nude rat 
infected with 
aureus to 
monitor 
antibiotic 
therapy 
efficacy 
able to image bacterial 
infections in animals with 
future applications in 
clinics 
Zhang Z 
[37] 
M. tuberculosis 
pyrazinamid
e analog 
halogen 
exchange 
reaction 
18F 
2.6 × 106 
kBq/μmol 
60% 
labelling 
efficiency 
(LE) at 90′ 
in livers 
 
C3HeB/F
eJ 
bone, lungs lungs - 
uninfected 
animals 
- 
successful radio-synthesis, 
higher uptake by infected 
lungs 
Ebenhan T 
[38] 
M. tuberculosis                       
S. aureus 
 TBIA101 
(depsidomyc
in 
derivative) 
DOTA chelator 68Ga 13 ± 6 GBq/μmol - 
New 
Zealand 
white 
rabbits 
kidneys 
108, thigh 
muscle 
2.8 ± 0.16 and 
2 ± 0.31 at 1 h 
for M. 
tubercolosis 
thigh 
(MTB)/triceps 
and 
MTB/thigh 
turpentine 
oil, 
contralateral 
or M. 
tubercolosis, 
contralateral 
- 
imaging inflammation with 
turpentine oil, but not 
infection. Non-specific 
Ordonez 
AA 
[39] 
E. coli and P. 
aeruginosa 
S. aureus  
M. tubercolosis     
PABA, 
mannitol, 
FDS 
- 
3H for 
PABA 
and 
mannitol, 
18F for 
FDS 
- - 
CBA/J 
mice  
kidneys 
106 S. aureus 
(PABA), 107 
E. coli 
(mannitol 
and FDS), 
right thigh 
- 
heat killed 
bacteria, left 
thigh 
- 
have significant potential 
for clinical translation for 
the rapid diagnosis of 
bacterial infections 
Zhang XM 
[40] 
S. aureus  
Fialuridine 
(FIAU) 
- 124I 
999–1295 
GBq/μmol 
- 
patients 
suspected 
of 
prosthetic 
joint 
infection 
(PJI) 
kidneys - - - - 
124I-FIAU is well tolerated 
but of limited value for 
detection of PJI due to low 
image quality and low 
specificity 
Wiehr S 
[41] 
Y. enterocolitica  
polyclonal 
monoclonal 
Antibody 
(mAb) vs 
1,4,7-triazacycl
ononane,1-glut
aric 
acid-4,7-acetic 
64Cu 
650–730 
MBq/mg 
90% up to 
48 h both 
in saline 
and 
C57BL/6 
mice 
spleen  103–104, i.v. - 
PBS and 
blocking 
experiments 
comparison 
with FDG 
rapid, sensitive and specific 
imaging probe  
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Yersinia 
adhesin A 
(YadA) 
acid 
(NODAGA) 
chelator 
serum 
Yao S 
[42] 
E. coli  FDS 
nucleophilic 
fluorination 
18F 
29.6 ± 6.5 
GBq/μmol 
95% up to 
2 h in 
serum 
C57BL/6 
mice 
kidneys 
105–107, right 
thigh 
2.05±0.07 and 
13.0±1.35, 
inflammation 
vs infection 
turpentine 
oil, left thigh  
comparison 
with FDG, 
human 
studies 
promising probe for 
diagnosis and monitoring 
therapy 
Rolle AM 
[43] 
A. fumigatus JF5 mAb DOTA chelator 64Cu - 
up to 48 h 
in serum 
neutrope
nic 
C57BL/6 
mice 
lungs, liver, 
spleen 
4 × 106, lungs 
11.9 ± 1.3, 7.7 
± 2, 8.1 ± 0.6, 
8.1 ± 1.5 
(%ID/cc for A. 
fumigatus, 
PBS, S. 
pneumoniae, 
Y. 
enterocolitica)  
106 S. 
pneumoniae, 
5 × 104 Y. 
Enterocolitica 
or PBS 
comparison 
with FDG 
and blocking 
experiments 
mAb localized aspergillus 
infection. FDG is 
non-specific for imaging 
infection 
Vilche M 
[44] 
S. aureus  UBI-29-41 NOTA chelator 68Ga 0.55 × 106 3 h 
M. 
musculus 
Swiss 
mice 
kidneys 
1.2 × 108, left 
thigh 
(measured in 
vitro 5 × 108–
1.2 × 109 and 
as low as 2.5 × 
104)  
infection 5 (in 
vitro) 1 h             
inflammation 
1.6 (in vitro), 1 
h                        
4.0 (PET), 1 h                      
Non-significa
nce 
inflammation
/normal 
(1) 1.2 × 108 
heat killed, 
left thig 
(2) healthy 
mice  
- 
clearly observed different 
uptake in infection vs. 
inflammation positively 
correlated with degree of 
infection 
Mokaleng 
BB 
[45] 
E. coli 
 TBIA101 
(depsidomyc
in 
derivative) 
DOTA chelator 68Ga 
12.4 ± 6 
GBq/μmol 
>97% up 
to 3 h in 
serum 
BALB/c 
mice 
liver, 
kidneys 
5 × 108, right 
thigh 
3 ± 0.8 
(infection) vs 
2.3 ± 0.6 
(inflammatio
n) 
healthy 
muscle 
- 
promising agent but need 
further studies 
Mills B 
[46] 
S. aureus  FDG-6-P - 18F 
injected activity            
8–11 MBq (FDG 
and FDG-6-P) 
3 h 
BALB/c 
mice 
kidneys 
1x109, via 
catheter in 
right flank 
~3.0 
(FDG-6-P) 
~1.0 (FDG) 
saline, via 
catheter in 
right flank 
- 
in vitro validated method, 
but very different behavior 
in vivo with high 
background, FDG-6-P 
accumulation had higher 
T/NT ratio than FDG = 
potential to differentiate 
infection from 
inflammation 
Severin GW 
[47] 
A. fumigatus 
free 89Zr 
(oxalate 
form) 
direct labelling 89Zr 20–35 GBq/μmol - 
neutrope
nic 
C57BL/6 
kidneys 
4x106, 
intratracheal 
6.3 vs 3.8 
healthy 
neutropenic 
mice 
- 
injection of  
free 89Zr (oxalate at pH < 7), 
routinely be performed  
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mice as a control experiment 
Weinstein 
EA 
[48] 
Enterobacteriace
ae  
FDS 
nucleophilic 
fluorination 
18F - - 
CBA/J 
mice  
intestine, 
kidneys 
107, right 
thigh 
- 
107 heat 
killed, left 
thigh; mixed 
infection 
with aureus; 
brain tumor 
comparison 
with FDG 
diagnostic tool for imaging 
infections due to 
Enterobacteriaceae 
Ning X 
[49] 
E. coli  
maltohexaos
e 
nucleophilic 
fluorination 
18F - - rats 
spleen, 
kidneys 
105–7, left 
triceps 
8.5 at 70′ 
PBS or 109 
killed, right 
triceps 
comparison 
with FDG 
sensitive, specific 
radiopharmaceutical that 
can identify drug resistance 
Gowrishan
kar G 
[50] 
E. coli  maltose 
nucleophilic 
fluorination 
18F - - 
nude 
mice and 
BALB/c 
mice 
kidneys 
5 × 107, right 
thigh 
4.2 at 3 h 
108 heat 
killed, 
contralateral 
and 
turpentine 
oil in BALB/c 
- 
promising new 
radiopharmaceutical for 
bacterial infection imaging 
Ebenhan T 
[51] 
S. aureus  UBI-29-41 NOTA chelator 68Ga 
injected activity             
27 ± 11/29 ± 
15/29 ± 15 MBq 
(normal 
controls/thighs 
/lung) 
4 h 
New 
Zealand 
white 
rabbits 
kidneys 
2 × 108, right 
thigh 
4.35 ± 0.85 
(infection/nor
mal) 3.54 ± 
0.86 
(infected/infla
mmation) 
turpentine 
oil, left thigh 
+ normal 
controls + 
lung 
inflammatio
n (asthma)  
- 
68Ga-UBI strongly localized 
in infection and only 
minimally in inflammation. 
No uptake in lung 
inflammation either 
Weinstein 
EA 
[52] 
M. tuberculosis 
isonicotinic 
acid (INH) 
nucleophilic 
fluorination 
18F 
7.4 to 11.1  
MBq/μmol 
- 
C3HeB/F
eJ mice 
and 
BALB/c 
mice 
kidneys, 
liver 
log10(6.4 ± 
0.3) CFU, 
lungs 
1.67 ± 0.04 
non-infected 
controls 
comparison 
with FDG 
rapid, non-invasive 
approach to localize 
infectious foci 
Petrik M 
[53] 
A. fumigatus 
siderophores
: 
triacetylfusa
rinine 
(TAFC) and 
ferrioxamine 
E (FOXE) 
direct labelling 68Ga 
9.2 × 104 and 3.4 
× 103 GBq/mmol, 
TAFC and FOXE 
- 
BALB/c 
mice for 
biodistrib
ution 
Lewis rat 
kidneys 
105–109 
conidia/ml, 
lungs 
5.81 ± 6.05 vs 
0.78 ± 0.75 
(TAFC), 6.64 
± 2.91 vs 1.0 ± 
0.81 (FOXE) 
as SUV 
non-infected 
controls 
- 
very promising agents for 
detection of infection with 
high sensitivity 
Panizzi P 
[54] 
S. aureus  
prothrombin 
(ProT) 
Diethylene 
triamine 
pentaacetic acid 
(DTPA) 
64Cu 
Injected doses           
0.92–1.62 mCi 
- 
C57BL/6 
mice 
- 
1 × 106/μL, 
aortic valve 
Only visual 
assessment 
Non-infected 
controls 
- 
non-invasive detection of S. 
aureus induces endocarditis 
is feasible with an 
engineered analog of 
prothrombin 
Martínez 
ME 
[55] 
E. coli  
fluoroacetam
ido-D-gluco
pyranose 
microwave 
irradation 
18F 
18.09 ± 2.9 
GBq/μmol 
- 
 
Sprague-
Dawley 
kidneys 
107, right 
thigh 
0.54 ± 0.21 vs 
0.19 ± 0.07  
turpentine 
oil 
comparison 
with FDG 
promising infection agent 
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(FAG) rats 
Kumar V 
[56] 
S. aureus  
Transferrin 
(TF) 
apo 68Ga 
Injected 
dose:10–15 MBq 
6 h 
Wistar 
rats 
- 
5 × 105, right 
thigh 
2.2-7.5 - - 
68Ga-TF is capable of 
detecting S. aureus infection 
Diaz Jr. LA 
[57] 
S. aureus  FIAU - 124I 
318 × 106 (8.596–
13.979 Ci/mmol) 
- 
patients 
suspected 
of 
musculos
keletal 
infections 
(n=8) 
kidneys 
various 
locations 
- 
1 control 
patient 
surgery as 
gold standard 
promising new method, but 
preliminary data 
Satpati D 
[58] 
S. aureus  ciprofloxacin 
DOTA and 
NOTA 
chelators 
68Ga 
6.2 ± 0.4 
MBq/nmol 
both in 
saline 
and 
serum up 
to 4 h 
Wistar 
rats 
kidneys 
5 × 107, right 
thigh 
1.5 for DOTA, 
5 for NOTA 
turpentine 
oil, left thigh  
- need further investigations 
Langer O 
[59] 
Gram-positive 
Gram-negative 
ciprofloxacin 
nucleophilic 
fluorination 
18F 
342 ± 94 
MBq/μmol 
- 
4 patients 
with 
proven 
soft tissue 
infections 
- - 
at peak 
uptake SUV = 
5.5 
  - 
not suitable as specific 
agent 
Petrik M 
[60] 
A. fumigatus 
TAFC and 
FOXE 
direct labelling 68Ga 
3.4 × 106 (FOXE) 
MBq/mmol 
80% 
(TAFC) 
and 90% 
(FOXE) at 
2 h in 
serum 
rats lungs n.a./left calf - 
turpentine 
oil and 109 
CFU of S. 
aureus (i.m.)  
comparison 
with FDG 
high selective accumulation 
in infected lungs 
Rajamani S 
[61] 
engineered E. 
coli and P. 
aeruginosa 
FIAU 
nucleophilic 
fluorination 
18F - - 
CD1 mice 
and 
BALB/c 
mice 
gastrointest
inal tract 
105, 107, 109, 
thigh 
- 
P. aeruginosa 
infection 
therapy with 
ciprofloxacin 
engineered pathogens for 
evaluating experimental 
therapeutics 
Zhang Z 
[62] 
S. aureus PABA 
Radio-synthesis 
box 
18F 
240.5 ± 77.7 
GBq/μmol 
- 
Sprague-
Dawley 
rats 
kidneys 
108, left 
triceps 
5 at 1 h 
heat killed, 
contralateral 
comparison 
with FDG 
novel, non-invasive 
diagnostic tool for 
detecting, localizing, and 
monitoring S. aureus 
infections 
J. Clin. Med. 2019, 8, 197 10 of 25 
 
Table 2. Summary of QUADAS analysis. 
 Risk of Bias Applicability Concerns 
First author [ref] 
Animal 
Selection 
Index 
Test 
Reference 
Standard 
Flow and 
Timing 
Animal 
Selection 
Index 
Test 
Reference 
Standard 
Gram-positive 
Bhatt J [28]               
Nielsen KM [29]               
Takemiya K [31]               
Ebenhan T [32]               
Pickett JE [34]               
Zhang XM [40]               
Vilche M [44]               
Mills B [46]               
Ebenhan T [51]               
Panizzi P [54]               
Kumar V [56]               
Diaz Jr. LA [57]               
Satpati D [58]               
Langer O [59]               
Zhang Z [62]               
Gram-Negative 
Mutch CA [30]               
Li J [33]               
Wierhr S [41]               
Yao S [42]               
Mokaleng BB [45]               
Weinstein EA [48]               
Ning X [49]               
Gowrishankar G [50]               
Martìnez ME [55]               
Rajamani S [61]               
Gram-Positive and Negative 
Sellmyer MA [35]               
Gowrishankar G [36]               
Ebenhan T [38]               
Ordonez AA [39]               
Others 
Zhang Z [37]               
Rolle AM [43]               
Severin GW [47]               
Weinstein EA [52]               
Petrik M [53]               
Petrik M [60]               
Green:”+”, Red: “−“, Yellow: “?”. 
3.2. Gram-Positive 
We included 15 studies for the analysis, excluding those that did not meet the inclusion criteria. 
In total, ten radiopharmaceuticals were considered in the QUADAS analysis. 
3.2.1. Fluorine-18 (18F)-Labelled Radiopharmaceuticals 
For many and well-known reasons, fluorine-18 was the first PET radioisotope of choice, i.e., a 
ubiquitous isotope with suitable half-life and well-established chemical properties. Thus, several 
potentially bacteria-specific radiopharmaceuticals labelled with fluorine-18 have been explored.  
Mills et al. looked at the alternative glucose analogue, [18F]FDG-6-phoshate, as a potential 
substrate for the bacterial universal hexose phosphate transporter (UHPT). UHPT is expressed in 
many bacteria species and provides the mechanism for sugar phosphate internalization in 
staphylococci in contrast to mammalian cells that are not able to directly transport sugar into the cell. 
The authors corroborated this premise in vitro by demonstrating very limited uptake of 
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[18F]FDG-6-phosphate in UHPT-deficient S. aureus and significantly less than regular strains. Uptake 
in various mammalian cell lines was limited to the same extent as in UHPT-deficient S. aureus and 
significantly different from S. aureus. However, these results did not translate in vivo in a mouse 
infection model when comparing uptake of [18F]FDG-6-phosphate to conventional [18F]FDG at 
indwelling catheters with or without inoculation with S. aureus. The authors surprisingly observed a 
biodistribution similar to [18F]FDG both visually and semi-quantitatively, and they established that 
this was not due to dephosphorylation of [18F]FDG-6-phosphate in the blood to yield [18F]FDG. 
Furthermore, in contrast with [18F]FDG, there was no accumulation of [18F]FDG-6-phosphate in 
sterile inflammation at the tip of the indwelling catheters in non-infected mice, although the 
[18F]FDG uptake was higher in infected areas compared to sterile inflammation [46]. According to 
the authors, this study suggests that the majority of radiopharmaceuticals never reaches the bacteria. 
The lack of bacterial origin could have introduced some bias in the study. 
Takemiya et al. looked at another modified pentasaccharide, 18F-labelled fluoromaltohexaose 
(FMH), targeting the maltodextrin transporter which has previously been explored in 
Gram-negative bacteria with comparable probes (see below) [31]. The target here was chosen 
because the uptake rates are high and the transporter is selectively expressed in bacteria. 
Furthermore, the substrates have limited toxicity to humans and the hydrophilic nature grants 
higher rates of clearance from non-infected tissues [63,64]. The authors investigated an infrared dye 
probe (MDP) detectable through the skin aimed at superficial (pocket) infections and the 
radiolabelled fluoromaltohexaose for deep infections. They compared both to each other and the 
latter also to [18F]FDG imaging in a rat model comparing microbially infected mock-up implants to 
sterile, turpentine-induced inflammation, and controls with no additional intervention besides the 
mock-up implants. The authors found corresponding visually increased uptake of MDP and FMH 
around the infected implants compared to both sterile inflammation and controls. For FMH, SUVmean 
and SUVmax were also significantly higher in the infected rats compared to sterile inflammation and 
controls. Not surprisingly, based on pre-clinical and clinical experience, [18F]FDG uptake around 
infected implants and in the controls corresponded to FMH but was also increased at sites of sterile 
inflammation. Thus, the authors found FMH a potential probe for specific bacterial imaging with the 
ability to differentiate sterile inflammation from infection. However, the authors pointed out the 
caveat of translation comparing their results to the successful pre-clinical results from Zhang et al. 
that were not confirmed when translated to humans [40]. The non-specified origin of bacteria, the 
unclear infection model used and imaging time might have introduced risks of bias in the QUADAS 
analysis. 
Langer et al. investigated 18F-labelled ciprofloxacin, an antibiotic previously labelled with 
techenetium-99m leading to discordant results. The alleged bacteria specific binding site is the 
topoisomerase II enzyme, the therapeutic target for ciprofloxacin. The authors performed in vitro 
pharmacokinetic studies and studied basic uptake mechanisms in vitro, albeit with Gram-negative 
E. coli. They concluded that no apparent specific uptake mechanism was present – increased uptake 
of [18F]ciprofloxacin was rapidly cleared, and was unaffected by large amounts of unlabelled 
radiopharmaceutical, as also reported by others using [99mTc]technetium-ciprofloxacin [65]. Thus, 
the authors concluded that increased uptake was most likely due to non-specific physiologic 
increase in blood flow as part of the inflammatory response. Similar results were reached in four 
patients with Gram-positive soft tissue infection caused by ciprofloxacin sensitive microbes. Thus, 
although there was rapid uptake in infected tissue different from non-infected tissue, the 
time-activity curves and the efflux of radiopharmaceutical were similar, and just as reversible as 
time-activity-curves of blood cells also indicating that non-specific processes such as blood flow is 
more likely to account for the difference in uptake than specific intracellular binding [59]. The 
unclear mechanism of patients’ selection could be source of bias as well as the non-specified 
reference standard and study flow. 
Recently, Zhang and colleagues radiolabelled the para-aminobenzoic acid (PABA) with 
fluorine-18 with the aim to detect S. aureus infection rat model and monitor drug response. Results 
showed a rapid renal clearance and an evident localization of 2-[18F]F-PABA in the infectious lesions 
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in comparison to sterile inflammation induced by using heat killed bacteria. Authors suggested that 
2-[18F]F-PABA might be a novel radiopharmaceutical for rapid and non-invasive imaging of a wide 
range of infections [62]. No sources of bias were reported for this study. 
In summary, two of the 18F-labelled radiopharmaceuticals were able to discriminate the 
presence of bacteria from sterile inflammation or healthy control and, when compared to [18F]FDG, 
they showed better results. However, poor specificity was observed for [18F]ciprofloxacin in vitro 
and in vivo, and the authors questioned the presence of a bacteria-specific uptake mechanism. In the 
QUADAS analysis, the main source of bias was related to unspecified origins of animals or bacteria. 
3.2.2. Gallium-68 (68Ga)-Labelled Radiopharmaceuticals 
The first study describing a 68Ga-radiopharmaceutical for imaging infections was published by 
Kumar et al. in 2011 and focused on the role of iron metabolism for bacterial growth [56]. It is 
well-known that tight regulation of iron availability is a key component in the human host response 
to bacterial invasion; concentrations of circulating free iron is too low to sustain bacterial growth so 
bacteria had to develop methods to acquire the necessary amounts from the abundance of iron 
bound to transport proteins like transferrin, e.g., siderophores or transferrin binding proteins like S. 
aureus does [66,67]. Since transferrin’s ability to bind Ga-ions is similar to its iron-binding ability, the 
exploration of a radioactive Ga-transferrin complex seemed an obvious choice as a potential bacteria 
specific radiopharmaceutical [56]. Infection was induced by intramuscular inoculation, and 
subsequent imaging with [68Ga]apo-transferrin showed focal time-dependent uptake at the site of 
infection. Increased uptake was also seen in one patient with an incidental wound infection by 
Proteus mirabilis. The authors also tested pure, unconjugated [68Ga]GaCl3 as control and no uptake 
was seen at the sites of infection. However, the paper states no information on reference standard for 
infection other than clinically established abscess at the site of inoculation which weakens the 
conclusion somewhat, introducing high risks of bias for QUADAS analysis. Another approach with 
gallium-68 was explored by two different groups using [68Ga]gallium-NOTA-UBI-29-41, a synthetic 
fragment derived from the antimicrobial peptide ubiquicidin that is part of the human first line 
response towards pathogens. The radiopharmaceutical had already been successfully explored 
labelled with techenetium-99m and was able to differentiate infection from sterile inflammation and 
tumours, both in vitro and in vivo, in both animals and humans [32,44,51,65], presumably the 
cationic antimicrobial peptide fragments interact electrostatically with anionic parts of the bacterial 
membrane [51,32].  
In the first paper, Ebenhan et al. studied the normal biodistribution in rabbits. Furthermore, 
they found significantly increased uptake in muscular abscesses as compared to turpentine-induced 
sterile muscle inflammation, asthma-like lung inflammation and healthy controls. The 
target/non-target (T/NT) ratios were as high as 5-fold higher for infected muscle, whereas ratios 
between inflamed and normal muscle as wells as ratios between inflamed and normal lung tissue 
were almost similar [51]. The unclear origin of animals and used infection model might be sources of 
bias. 
Vilche et al. used a similar setup, albeit with mice and heat shock-treated bacteria instead of 
turpentine for sterile inflammation, but their results were similar to those published by Ebenhan 
[44]. However, the non-specified origin of animals and unclear infection model used in the study 
might have introduced risks of bias.  
In a recent study, Bhatt et al. carried out several sub-studies on [68Ga]gallium-UBI-31-38 
including in vitro tests for purity and stability and the assessment of uptake specificity in S. aureus. 
In vivo imaging was performed in an animal model of infection comparing the uptake in muscle 
inoculated with living S. aureus to muscle inoculated with heat-killed S. aureus. Finally, they 
undertook preliminary clinical studies in two patients and one control subject. In vitro they 
demonstrated a high and specific [68Ga]gallium-UBI-31-38 uptake in S. aureus. In preclinical studies 
they found a significantly higher uptake in infected muscle versus inflamed muscle with a 
T/NT-ratio of 3.24  0.7. The clinical pilot study demonstrated high [68Ga]gallium-UBI-31-38 uptake 
in infectious foci in the lungs and diffusely around a knee prosthesis, both confirmed with biopsy, 
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whereas no uptake was seen around a suspected hip prosthetic infection later confirmed to be 
non-septic inflammation. However, the reference standard for the preclinical trials are difficult to 
assess and the patient cases were highly selected and with very different infectious sites with no data 
presented on the underlying infections afterwards. The authors concluded that the method is 
promising, but still needs further validation [28]. 
In a similarly recent paper, Ebenhan et al. also performed a small first-in-man study with 
[68Ga]gallium-NOTA-UBI following successful in vitro assessment of cytotoxicity, and preclinical 
biodistribution and dosimetry studies in mice. In this study, [68Ga]gallium-NOTA-UBI uptake in 
knees was found in all three patients with suspected or known soft-tissue or bone infections, but not 
in the two healthy controls. No information is provided on the bacterial strains involved or if any 
bacteria was cultured at all, because all diagnoses of infection were based on other imaging 
modalities like bone scintigraphy and white-blood-cell scintigraphy. Authors also concluded that 
the method is promising, but with the need for further evaluation [32].  
Nielsen et al. investigated the peptide A9 supposed to bind to S. aureus biofilm to establish its 
ability to distinguish infection from turpentine-induced sterile inflammation compared to [18F]FDG. 
Both radiopharmaceuticals showed increased uptake in both infection and inflammation with no 
discernable differences, although [18F]FDG was false negative in two cases. Furthermore, A9 uptake 
was higher in inflamed lesions as compared to infections. The authors speculated and then 
confirmed what the precise target of the A9 peptide was the cell membrane of dead bacteria [29]. The 
non-specified origin of bacteria and the unclear infection model used and study flow could be source 
of bias, resulting in applicability concerns too.  
Finally, Satpati et al. investigated ciprofloxacin once more, but labelled with gallium-68 with 
two different ligands. In vitro studies demonstrated only limited binding to bacterial cells, but when 
radiopharmaceutical uptake was compared in vivo in infected and turpentine induced inflamed soft 
tissue abscess there was increased uptake in both infection and inflammation, but more so in 
infection [58]. The unclear origin of animals might have introduced bias in the QUADAS analysis, 
leading to concerns about applicability too. 
In summary, most 68Ga-labelled radiopharmaceuticals are promising and potential agents for 
distinguishing infection from sterile inflammation, but two studies were equivocal and further 
investigations were suggested [32,58]. The only radiopharmaceutical that was not shown to be 
selective for bacterial imaging was [68Ga]gallium-DOTA-A9 [29]. In the QUADAS analysis, the 
non-specified or unclear origin of animals and bacterial cells are the main causes of potential bias. 
3.2.3. Zirconium-89 (89Zr)-Labelled Radiopharmaceuticals 
Pickett et al. looked specifically at S. aureus-infected prosthetic joint and assessed by a 
89Zr-labelled monoclonal antibody (mAb) directed against the specific Gram-positive surface 
molecule lipoteichoic acid ([89Zr]zirconiumSAC55). Binding affinity was tested in vitro, and the 
diagnostic effectiveness for differentiating aseptic and septic prosthetic joint infection was tested in 
vivo in a mouse model and compared to [18F]FDG, [18F]NaF, and conventional CT with 
bioluminescent imaging as the reference standard. [89Zr]zirconiumSAC55 had significantly higher 
uptake in infected areas compared to sterile prostheses sites as well as control radiopharmaceutical 
without bacterial affinity. Similar to the human experience, [18F]FDG and [18F]NaF demonstrated 
increased uptake at infected sites as well as in areas of sterile postoperative inflammation, thus 
underlining radiopharmaceutical inability to distinguish active infection from background 
inflammation or slow indolent infections with low bacteria burden. Interestingly, zirconium-89 was 
chosen for its relatively long half-life (78 h) because of the long clearance time of mAbs necessitates 
delay between injection and imaging to optimize target-to-background ratio, but in this study the 
authors found that optimal imaging time was at 24 h post-injection [34]. No sources of bias were 
reported for this study.  
3.2.4. Copper-64 (64Cu)-Labelled Radiopharmaceuticals 
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A special feature of S. aureus is its ability to initiate bacterial colonization under flow conditions 
at sites of endothelial damage. A key element, albeit not completely understood, is the effects of 
staphylocoagulase that enables S. aureus to clot blood and evade the host immune response. Panizzi 
et al. looked specifically at the role and expression of this enzyme by way of a prothrombin analogue 
able to form a SC-prothombin complex. For PET-imaging the prothrombin analogue was chelated 
with DTPA and subsequently labelled with copper-64 ([64Cu]copper-DTPA-ProT). The authors 
found a robust accumulation of the radiopharmaceutical at infected vegetation in a mouse 
endocarditis model, whereas control mice with endothelial damage but no infection demonstrated 
no uptake of [64Cu]copper-DTPA-ProT. The presence of infection was corroborated by 
bioluminescent S. aureus strains which correlated well with radiopharmaceutical uptake both in vivo 
and at ex vivo autoradiography of the infection targets in the aortic root. Additional in vivo 
experiments also substantiated the findings; a substantially increased accumulation was seen in S. 
aureus compared to mice without bacteraemia and mice infected with coagulase negative S. 
epidermidis. Similarly, no uptake was present in mice infected with coagulase deficient S. aureus 
strains [54]. For this study, the QUADAS analysis reported some bias concerning the unclear origin 
of animals, the methodology of experiments and study flow.  
3.2.5. Iodine-124 (124I)-Labelled Radiopharmaceuticals 
The nucleoside analogue 1-2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl-5-iodouracil (FIAU) was 
initially explored as an anti-viral drug, but was discontinued due to severe toxicity. Later it was 
discovered serendipitously to be a substrate for thymidine kinases in several bacteria; it enters cells 
freely and become trapped inside the cells after phosphorylation and, as a diagnostic agent, the 
required dose is well below the limit of toxicity. Furthermore, it is not a significant substrate for the 
most abundant human thymidine kinases thereby making it an interesting radiopharmaceutical for 
infection imaging. The choice of a long-lived radioisotope as iodine-124 with a half-life of 4.2 days 
was based on practical considerations (better production and transport logistics and better chemical 
yield than fluorine-18) as well as clinical considerations (the possibility of late imaging, as chronic 
prosthetic joint infections may involve relatively slow-growing bacteria) [40,68]. 
Diaz et al. examined eight patients, and one healthy control. Scans were positive in 7/8 patients 
with positive culture in 6/7 and negative culture in one patient who was however deemed positive 
for infection nonetheless due to clinical history and findings. Scan was negative in one patient with 
resolution of symptoms without surgery or antibiotics and in the healthy control subject. Thus, the 
results seemed promising, but the whole-body distribution showed significant uptake in liver, 
kidneys, muscles and to a lesser extent in several other organs, due in part to the presence of a 
mitochondrial enzyme resembling the bacterial TK. This may hamper the general applicability in 
suspected infections in these organs. The target TK is considered specific for bacteria and therefore 
potentially able to differentiate infection from non-infectious inflammation. This was supported as 
the healthy control had osteoarthritis in a knee which showed no uptake, but, on the other hand, in 
the one patient with positive uptake but negative culture, the biopsy showed chronic inflammation. 
This was attributed to infection, but it may be that non-infected inflammation was the cause of 
uptake which would also hamper the clinical use of this radiopharmaceutical [57]. It is also worth 
noting that patients were probably highly selected, albeit no data is presented on patient selection, 
leading to high risk of bias in the QUADAS analysis. 
Zhang et al. assessed the same radiopharmaceutical in the setting of suspected prosthetic joint 
infection (PJI) [40]. A preliminary phase I study in 6 patients and 6 healthy controls established its 
biodistribution, dosimetry and safety, but the phase II study did not confirm the promising results of 
the abovementioned study by Diaz et al. Indeed, in 19 patients suspected of PJI, four were treated as 
positive with final diagnosis determined by an independent adjudication board with access to all 
information. However, increased background uptake in muscles and artificially increased uptake 
around the prosthesis due to metal artefacts and attenuation obscured any pathologic activity and 
rendered the differentiation between infected and non-infected prosthesis impossible. Various 
semi-quantitative approaches (e.g., TBR and SUVmax) were also unsuccessful. Thus, the authors 
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concluded that while well-tolerated and with acceptable dosimetry, the clinical applicability seems 
limited due to poor image quality and low specificity, at least in suspected PJI or other settings with 
metal artefacts or very low bacterial burden. The unclear patients’ selection process and the not-well 
specified index test and reference standard might have led to the presence of bias in the QUADAS 
analysis. 
3.3. Gram-Negative 
We included 10 studies for the analysis, excluding those that did not meet the inclusion criteria. 
In total, 8 radiopharmaceuticals and 4 different bacterial strains were considered in the QUADAS 
analysis. 
3.3.1. Carbon-11 (11C)-Labelled Radiopharmaceuticals 
Mutch and colleagues radiolabelled PABA with carbon-11 to study the targeting of bacterial 
metabolism in E. coli mice infection model, using heat-killed bacteria as control. They showed a 
significant uptake of radiopharmaceutical in the infectious site compared to inflamed foci, 
concluding that [11C]carbonPABA is an attractive candidate to image living bacteria in humans [30]. 
No potential source of bias was reported for this study.  
3.3.2. Fluorine-18 (18F)-Labelled Radiopharmaceuticals 
As aforementioned, fluorine-18 is one of the most studied PET isotopes and many compounds 
radiolabelled with 18F have been explored for imaging of Gram-negative bacteria. 
Yao et al. compared the biodistribution and specificity of 18F-2-fluorodeoxysorbitol ([18F]FDS) to 
[18F]FDG in a E. coli mouse infection model and in humans. They concluded that [18F]FDS is a 
potential imaging agent for the diagnosis of Enterobacteriaceae infections in preclinical setting. 
Given the lack of adverse events and rapid clearance through the urinary system, it could easily 
enter into clinical practice [42]. Potential bias may have been introduced by the fact that the origin of 
animals and bacterial cells was non-specified in the paper. Therefore, lack of reproducibility may 
also be a critical issue. The ability of [18F]FDS to discriminate septic from sterile inflammation has 
also been investigated by another group in several Enterobacteriaceae infection mouse models 
comprising E. coli infection, mixed infection with E. coli and S. aureus, K. pneumoniae infection and 
brain infection. Results showed that [18F]FDS was able to image infectious foci with higher specificity 
when compared to [18F]FDG. Therefore, it could be a candidate imaging radiopharmaceutical of 
Enterobacteriaceae infections to be translated into humans [48]. Also in this study, the lack of any 
information about animal origin could have introduced some biases. Moreover, the use of different 
SUV scale between [18F]FDS and [18F]FDG-PET acquisition could have been another source of bias in 
the QUADAS analysis. Recently, the selectivity and sensitivity of [18F]FDS have been also 
investigated in K. pneumoniae lung infection animal model by Li and colleagues. They compared this 
radiopharmaceutical with [18F]FDG in septic and aseptic inflammatory condition [33]. Authors 
reported higher specificity of [18F]FDS rather than [18F]FDG, not only in discriminating septic from 
sterile inflammation, but also Gram-negative from Gram-positive bacteria, proposing [18F]FDS as 
new clinical standard imaging agent for lung infection. No sources of bias were reported for this 
study. 
Then, Ning et al. performed a study to evaluate the sensitivity and specificity of fluorine-18 
radiolabelled maltohexaose ([18F]MH) that targets the bacteria-specific maltodextrin transporter, in 
E. coli infection preclinical model. They investigated both [18F]MH and [18F]FDG in several 
experimental conditions such as the use of different bacterial amounts, live and dead bacteria and 
drug-resistant E. coli. They demonstrated a better in vivo performance of [18F]MH than [18F]FDG for 
detection of infection at early stage and identification of drug resistance. Therefore, they concluded 
that it is a potential radiopharmaceutical to be introduced in clinical practice [49]. No potential 
sources of bias were reported for this study. 
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Recently, the 6′’-[18F]fluoromaltose was investigated as specific imaging radiopharmaceutical of 
bacterial infection by Gowrishankar et al. [50]. Results showed that 6′’-[18F]fluoromaltotriose is taken 
up by viable E. coli infected muscle rather than control infected with heat-inactivated bacteria, 
discriminating between infection and inflammation. The lack of animal origin could have 
introduced biases in the study, thus limiting its applicability. 
Martìnez and colleagues developed the 2-deoxy-2-[18F]fluoroacetamido-D-glucopyranose 
([18F]FAG) with the aim to evaluate its specificity for bacterial infection in E. coli infection rat model 
in comparison to [18F]FDG. They reported higher and significant uptake of [18F]FAG in infectious foci 
than inflammatory sites, whereas [18F]FDG showed a similar uptake in infectious and inflammatory 
lesions, suggesting that [18F]FAG could be a promising bacterial infection PET imaging agent [55]. 
No potential sources of bias were reported for this study. 
Recently, the [18F]FIAU ability to detect bacterial infection was studied in a mouse model 
injecting different amounts of wild type and thymidine kinase (TK)-engineered P. aeruginosa. Results 
demonstrated that the TK-engineered P. aeruginosa is a useful tool to study bacterial infection in a 
preclinical setting and [18F]FIAU revealed to be an attractive radiopharmaceutical for detecting 
bacteria and evaluating drug efficacy [61]. Also in this study, the lack of animal origin could have 
introduced some biases. However, it is also worth noticing (see above) that previous studies with a 
124I-labelled equivalent fell short when translated into clinical human trials [40].  
In summary, all 18F-labelled radiopharmaceuticals were able to discriminate the presence of 
Gram-negative bacteria from sterile inflammation or healthy control and, when compared to 
[18F]FDG, they showed better results. The QUADAS analysis revealed that the main source of bias 
was related to the unspecified origins of the used animals or bacteria. 
3.3.3. Copper-64 (64Cu)-Labelled Radiopharmaceuticals 
Infection caused by Y. enterocolitica was induced in C57BL/6 mice to study the ability of 
[64Cu]copper-NODAGA-labelled Yersinia-specific polyclonal antibodies targeting the outer 
membrane protein YadA in comparison to [18F]FDG. Experimental data showed a rapid, sensitive 
and specific detection of infection by the radiopharmaceutical, whose uptake decreased after 
blocking [41]. The non-specified origin of animals and bacterial cells might have introduced risks of 
bias for the QUADAS analysis. 
3.3.4. Gallium-68 (68Ga)-Labelled Radiopharmaceuticals 
A depsidomycin derivative, TBIA101, was radiolabelled with gallium-68 in order to investigate 
its specificity in BALB/c mice infected with E. coli for targeting bacterial lypopolisaccharide (LPS) 
with PET/CT. Because of suboptimal imaging results, further studies are required to confirm its 
potential as a radiopharmaceutical to image infection [45]. As a possible bias of the study, the 
selection of animals was not clarified in the text and the reference standard was not accurately 
chosen. Moreover, the small number of included animals could lead to difficult evaluation of future 
applicability. 
3.3.5. Gram-Positive and Negative 
As patients can normally not be categorized as being infected with either Gram-positive or 
Gram-negative species when imaging is employed to find occult infectious foci, for a 
radiopharmaceutical to be sufficiently sensitive to be employed upfront in the diagnostic workup, it 
should detect both overall groups while still not be taken up in sterile inflammation or cancer cells. 
Thus, some authors have looked into this by exploring potential radiopharmaceuticals in settings 
with both Gram-positive and Gram-negative bacteria.  
Ordonez et al. tested three potential radiopharmaceuticals based on an elaborate screening 
procedure with subsequent in vitro testing: para-aminobenzoic acid (PABA) (with uptake in several 
different bacterial strains including mycobacteria, E. coli, and S. aureus), mannitol (with uptake in S. 
aureus and E. coli), and sorbitol (with uptake in E. coli only). All three molecules were tested in a 
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mouse model of myositis with fluorine-labelled analogs that accumulated significantly more in 
viable bacteria compared to heat-killed bacteria. However, only [18F]FDS is readily available as a true 
fluorine-based radiopharmaceutical, whereas PABA and mannitol were tested as fluorinated 
analogs. Thus, although potentially useful, a significant preclinical testing program is necessary 
before translational evaluations are possible for the two most versatile molecules (PABA and 
mannitol), whereas [18F]FDS is readily available, but has the narrowest usage (E. coli only) [39]. 
Gowrishankar et al. evaluated 6”-[18F]-fluoromaltotriose, a second-generation 
radiopharmaceutical targeting the bacteria specific maltose-maltodextrin transporter unique to 
bacteria and present in various both Gram-positive and Gram-negative species including S. aureus, 
E. coli, and P. aeruginosa. Maltotriose was investigated because previous studies of fluoro-labelled 
maltose and maltohexose showed a less favorable biodistribution profile with poor signal-to-noise 
ratio especially in the pulmonary organs. 6”-[18F]-fluoromaltotriose was tested in several in vitro 
settings to establish a better biodistribution profile. Subsequently, a myositis mouse model was 
employed to compare uptake in viable E. coli compared to uptake in heat-killed E. coli. Furthermore, 
a P. aeruginosa wound model was investigated. The uptake of 6”-[18F]-fluoromaltotriose was 
significantly higher in viable bacteria compared to dead bacteria and normal tissue. The authors also 
performed a response evaluation study in a single rat with incidental S. aureus infection – high 
specific uptake at the site of infection subsided significantly following relevant antibiotic treatment. 
Thus, 6”-[18F]-fluoromaltotriose has the potential to image several different bacteria species, albeit 
without the ability to differentiate between them. Results also pointed to less favorable results for 
bacteria that invade cells, e.g., M. tuberculosis [36]. 
Sellmyer et al. bioengineered a novel fluorine-18 labelled radiopharmaceutical based on the 
antibiotic trimethoprim ([18F]FPTMP) targeting the enzyme dihydrofolate reductase (dhfr) in the 
DNA synthesis and known to have higher affinity for bacterial dhfr than human dhfr. Promising in 
vitro results established a favorable biodistribution and significantly higher uptake in viable bacteria 
compared to heat-killed bacteria. Subsequently, a mouse myositis model was employed to test 
uptake in S. aureus, E. coli, and P. aeruginosa compared to turpentine-induced sterile inflammation, 
and implanted mammary carcinoma cells. The authors demonstrated a 3-fold increased 
target-to-muscle ratio in bacterial infections with E. coli and S. aureus, whereas no uptake was seen in 
P. aeruginosa, which was also corroborated by lower uptake in P. aeruginosa in vitro. No uptake was 
seen in sterile inflammation or cancer cells. Conversely, when [18F]FDG was employed in the same 
model, increased uptake was seen in all three etiologies. A caveat in the present study is the 
potential for resistance towards the antibiotic’s mode of action which may render such a 
radiopharmaceutical useless. Furthermore, when different inoculation amounts were tested, 
[18F]FPTMP was not able to detect infections by less than 108 CFU, suggesting that the number of 
infection cells play a role [35]. 
Finally, Ebenhan et al. investigated the Ga-68-labelled antimicrobial peptide TBIA101, a 
so-called depsipeptide derivative proposedly especially active against multidrug resistant 
mycobacterium species through interaction with the bacterial cell envelope. Following 
biodistribution studies, radiopharmaceutical uptake was evaluated in a mouse model with muscle 
infection (S. aureus or M. tuberculosis) compared to sterile turpentine-induced inflammation. 
Significantly increased radiopharmaceutical uptake was seen in M. tuberculosis infection (T/NT ratio 
of 2.6), but none in S. aureus infection. Furthermore, a similarly increased uptake with T/NT ratio of 
2.6 was also found in sterile inflammation. Thus, these results suggest a lack of bacterial selectivity 
for TBIA101 and therefore a limited usefulness in specific bacterial imaging [38]. 
In summary, three radiopharmaceuticals showed to be specific for bacterial infection imaging 
by using both Gram-positive and Gram-negative bacteria. However, all three demonstrated some 
caveats regarding the compounds’ applicability; one pointed to less favorable results for bacteria 
that invade cells, e.g., M. tuberculosis [36]; one was based on an antibiotic with the potential for 
limited use in case of resistance and also results pointing to less efficacy with smaller amounts of 
infective cells [35]; and one study reported a poor specificity for the studied radiopharmaceutical, 
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limiting its translation to humans [38]. The QUADAS analysis revealed that the main source of bias 
was related to unspecified origins of animals or bacteria. 
3.4. Other Pathogens  
Several microbial organisms not readily divisible into Gram-positives and Gram-negatives have 
also been subjected to more or less specific PET-radiopharmaceuticals other than [18F]FDG. Thus, we 
included 6 studies for the analysis, excluding those that did not meet the inclusion criteria. In total, 5 
radiopharmaceuticals and 2 different bacterial strains were considered in the QUADAS analysis. 
Invasive pulmonary aspergillosis (IPA) is a life-threatening lung disease caused by the fungus 
Aspergillus fumigatus, a leading cause of invasive fungal infection-related mortality and morbidity in 
patients with hematological malignancies and bone marrow transplants. Several 
radiopharmaceuticals labelled with various isotopes have been investigated. Petrik et al. explored 
different 68Ga-labelled radiopharmaceuticals: first, they described the uptake of 68Ga-siderophores, 
[68Ga]galliumTAFC and [68Ga]galliumFOXE respectively, in invasive pulmonary aspergillosis. Their 
research showed both [68Ga]galliumTAFC and [68Ga]galliumFOXE can be used for imaging of IPA 
with [68Ga]galliumFOXE being slightly superior in terms of sensitivity. [68Ga]galliumTAFC showed 
also high in vitro specificity towards A. fumigatus compared to other tested micro-organisms and 
human lung cancer cells. In the second study, the same group also used 68Ga-radiolabelled 
siderophores to visualize IPA in A. fumigatus-infected animals with μPET/CT. These small 
high-affinity chelating compounds are produced by fungi and bacteria to scavenge iron from the 
host, and by Gram-negative bacterial pathogens as virulence factors. The high metabolic stability, 
favorable pharmacokinetics with rapid renal excretion and high specific uptake in A. fumigatus 
cultures were confirmed in imaging studies in a rat IPA model that showed high focal uptake in 
infected lung tissue corresponding to pathological findings seen on CT. High specific uptake in A. 
fumigatus cultures is somewhat reduced under conditions of iron overload, which is what patients 
who acquire fungal infections typically suffer from [53,60]. Rolle et al. used their own newly 
developed [64Cu]copper-DOTA-labelled A. fumigatus-specific monoclonal antibody (mAb), JF5, in 
neutrophil-depleted A. fumigatus-infected mice, which allowed specific localization of lung infection 
when combined with PET/MR. This radiopharmaceutical distinguished IPA from bacterial lung 
infections and, in contrast to [18F]FDG-PET, discriminated IPA from a general increase in metabolic 
activity associated with lung inflammation [43]. Severin et al. showed, that [89Zr]zirconium-oxalate 
can exhibit substantial tumor accumulation as well as significant accumulation in Aspergillus 
infected lungs as compared to healthy lungs [47]. They suggest control experiments mapping the 
biodistribution of free zirconium-89 in any preclinical study employing zirconium-89 where bone 
uptake is observed. 
Mycobacterium tuberculosis was studied in the same model of infection by two groups that used 
two different radiopharmaceuticals. Weinstein et al. radiolabelled an analogue of isoniazid (INH) 
with fluorine-18 to verify its ability as a radiopharmaceutical for PET imaging of M. tuberculosis. 
They reported an increasing uptake of [18F]INH in tuberculosis (TB) lesions of infected animals over 
time in comparison to non-infected ones, proposing [18F]INH as a promising agent for identifying TB 
infection. [18F]FDG on the other hand was not able to discriminate between infection and 
inflammation [52]. The unclear origin of bacterial cells and reference standard might have 
introduced biases in the study. 
More recently, M. tuberculosis infection was studied in a preclinical model using an analogue of 
the first-line tuberculosis drug, the pyrazinamide (PZA), radiolabelled with fluorine-18. Results 
showed a successful radiolabelling procedure of the compound, but also a comparable distribution 
in TBC necrotic areas between infected and uninfected mice, thus limiting its potential use [37]. No 
sources of bias were reported for this study. 
4. Discussion 
Bacterial infections are still one of the main causes of mortality worldwide. Many efforts have 
been made to develop new specific radiopharmaceuticals for PET or SPECT imaging to improve the 
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overall diagnostic accuracy [69–71]. The continuous development of bacteria-specific imaging agents 
to discriminate between septic and sterile inflammation testifies the need for a highly accurate tool 
for infection diagnosis and therapy follow-up. 
In this setting, we have previously published a meta-analysis of SPECT radiopharmaceuticals 
for imaging bacteria [3] and we now performed a perceptive analysis of the literature concerning 
PET radiopharmaceuticals for bacterial imaging in preclinical studies. Considering the heterogeneity 
of included manuscripts, we divided them into four groups in relation to the bacterial strain to 
which the described radiopharmaceutical is directed. Each paper was analysed following the 
QUADAS guidelines that verify the risk of bias, quality of studies and applicability, adjusting these 
parameters to our papers (Appendix 1)  
Most of the authors that used Gram-positive bacteria reported the suitability of the tested 
radiopharmaceuticals for bacterial imaging in animal models but also in patients. In particular, the 
ubiquicidin peptide fragments, both UBI-31-38 and UBI-29-41, allowed to image foci of S. aureus 
infection in preclinical models with high T/NT ratios. Recently, UBI fragments were tested in 
humans and revealed to be safe and non-toxic, although further studies are needed to confirm 
preliminary results [28,32,44,51]. Other radiopharmaceuticals, like [124I]FIAU, were less encouraging 
when translated to patients despite initial promising results in animals [40]. Other groups showed 
high specificity of radiopharmaceuticals in the discrimination between infection and sterile 
inflammation, thus considering them as potential agents for bacterial imaging in humans [31,34,46]. 
Worth of mention is the case of radiolabelled ciprofloxacin: discordant data when labelled with 
technetium-99m, unsuccessful when labelled with fluorine-18 [59,29], and highly specific when 
labelled with gallium-68 [58]. These controversial results are probably due to the difference in 
isotopes used and the chemistry to label with different isotopes that may influence the biological 
behaviour of radiolabelled-ciprofloxacin.  
In the majority of papers on Gram-negative bacteria, promising results were reported by using 
radiolabelled sugars (sorbitol, maltose, maltohexaose and FAG). Indeed, several groups showed 
high specificity of [18F]FDS binding to E. coli or K. pneumoniae [33,42,48]. Also, other sugars such as 
FMH, 6′’-[18F]-fluoromaltose and [18F]FAG revealed to be sensitive and specific 
radiopharmaceuticals for detection of E. coli [49,50,55]. 
Regarding the QUADAS analysis for papers that used Gram-positive bacteria, the most 
frequent sources of bias were related to the origin of animals (about 50% of total articles) and the 
index test (about 50% of total articles), particularly the origin of bacterial cells and the not 
standardized infection model. Only two papers did not show risks of bias and applicability concerns 
in each section [62,34].  
QUADAS analysis of papers on Gram-negative bacteria, only four of them showed a low risk of 
bias and low concerns about applicability through an appropriate experimental procedure, avoiding 
the introduction of biases [30,33,49,55]. The most frequent source of bias was related to animal 
selection and index test (the origin of bacterial cells). Indeed, it is extremely important to clarify the 
origin of animals/bacteria with the aim to perform reproducible and standard methods. 
Some group used both Gram-positive and Gram-negative bacteria or a combination of the with 
M. tuberculosis to induce infection in preclinical models. Out of four papers, three reported good 
specificity of radiopharmaceuticals for bacterial infection imaging with future applications in clinics 
[35,36,39]. On the other hand, [68Ga]gallium-DOTA-TBIA101 was found to be non-specific when the 
infection was induced by using S. aureus or M. tuberculosis [38], while it was considered a promising 
agent for E. coli bacterial infection [45]. Indeed, [68Ga]gallium-DOTA-TBIA101 requires further 
studies to confirm its specificity for bacterial imaging and for which bacterial strain. 
Concerning QUADAS analysis for these papers, the most frequent sources of bias were related 
to the origin of animals or bacterial cells (50% of total articles). Only one did not show risks of bias 
and applicability concerns in each section [36]. 
Finally, all groups that tested radiopharmaceuticals to image M. tuberculosis and A. fumigatus 
infections in preclinical models, reported high sensitivity and specificity to localize infectious foci, 
making them promising agents for infection imaging in humans too [37,43,47,52,53,60].  
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Regarding QUADAS analysis for papers that used other bacteria (M. tuberculosis, A. fumigatus), 
five articles out of six (83.3%) presented low risks of bias. 
Overall results suggest that, despite promising initial findings, more studies are needed to 
further confirm the diagnostic use of any of the described radiopharmaceutical. Better study design 
with standardized and reproducible infection models, an appropriated reference standard and a 
pertinent study flow, are needed.  
Despite many overall promising results, no radiopharmaceutical has been introduced into 
clinical practice yet. This is probably because specific and non-specific mechanisms coexist at the 
infection site leading to a bias in the analysis of the results.  
The most critical issue that we observed in all studies is related to the infection model, controls 
and general experimental setting such as the amount of bacterial cells, the radiopharmaceutical dose, 
the imaging time after radiopharmaceutical injection, the different time interval between bacteria 
injection, the radiopharmaceutical administration route, and the imaging time points. In addition, 
none of the reviewed papers take into consideration possible bacterial mutations that may occur 
during an infection, thus changing their properties. These mutations may alter the 
radiopharmaceutical uptake that could lead to a false negative scan (i.e., during antibiotic therapy or 
during epidemic infections).  
The Teflon tissue cage model is a good example of what could be considered a standardised 
reproducible animal model to study bacterial infections [65,72]. Indeed, once implanted into the 
back of the mouse, it provides several advantages such as a localized infection, an accurate 
determination of bacterial mass and radiopharmaceutical concentration over time or the study of 
biofilm formation [73].  
The lack of common experimental models and procedures did not allow us to compare the 
results obtained using different radiopharmaceuticals and prediction of results in humans is 
difficult.  
Furthermore, in the light of data published so far, it emerges that there is the lack of knowledge 
whether it is possible to develop an all-purpose radiopharmaceutical to image all bacterial strains. 
Nowadays this remain an open goal, difficult to achieve, but, at the same time, crucial for the 
management, treatment and follow-up of patients with suspected bacterial infections. 
5. Conclusions 
This review highlights that several new PET radiopharmaceuticals for bacterial imaging have 
been developed with potential to be translated to humans for PET/CT imaging of infection. Despite 
initial promising results, however, many candidate compounds remain confined in a pre-clinical 
setting due to the presence of biases that limits their impact. When designing new studies, 
standardized protocols and models could ensure that time, funds, and research efforts are put to the 
best possible use. Indeed, the most frequent sources of bias found in selected articles were related to 
animal selection and index test and showed the lack of standardization with current infection 
models and experimental settings. Thus, standardized protocols and consensus guidelines 
regarding animal models of infection are needed, preferably written by a joint technical committee. 
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Appendix 1. QUADAS questionnaire for preclinical studies (top) and human studies (bottom). 
Domain Animals Selection Index Test Reference Standard Flow and Timing 
Signaling 
question (yes, no 
or unclear) 
Does the origin of animals 
come from company?  
Is the origin of bacterial cells 
certified ATCC?  
Is the used reference standard 
appropriated for the study?  
Is the imaging time appropriated 
for the study? Is it a standardized infection 
model?  
Can the radiopharmaceutical 
synthesis be a source of bias? 
(QCs, AS) 
Could the difference interval time 
between bacteria injection and 
radiopharmaceutical 
administration be a source of bias? 
Were further in vitro, in vivo, 
ex-vivo tests performed to 
support main results? 
Risk of bias (high, 
low or unclear) 
Could the selection of 
animals have introduced 
bias? 
Could the methodology of 
experiments have introduced 
bias? 
Could the reference standard or 
its interpretation have introduced 
bias? 
Could the study flow have 
introduced bias? 
Concerns about 
applicability 
(high, low, or 
unclear) 
Are there concerns that the 
included animals do not 
match the review question? 
Are there concerns that the 
index test or its interpretation 
differ from the review 
question? 
Are there concerns that the target 
condition as defined by the 
reference standard does not match 
the review question? 
- 
 
Domain Patients Selection Index Test Reference Standard Flow and Timing 
Signaling question 
(yes, no or unclear) 
Was a consecutive or random 
sample of patients enrolled? 
Were the index test results 
interpreted without 
knowledge of the results of 
the reference standard? 
Is the reference standard likely to 
correctly classify the target condition? 
Was there an appropriate 
interval between index tests 
and reference standard? 
Did all patients receive a 
reference standard? 
Did the study avoid 
inappropriate exclusions? 
Were the reference standard results 
interpreted without knowledge of the 
results of the index test? 
Did all patients receive the 
same reference standard? 
Risk of bias (high, 
low or unclear) 
Could the selection of 
patients have introduced 
bias? 
Could the conduct or 
interpretation of the index 
test have introduced bias? 
Could the reference standard or its 
interpretation have introduced bias? 
Could the study flow have 
introduced bias? 
Concerns about 
applicability  
(high, low, or 
unclear) 
Are there concerns that the 
included patients do not 
match the review question? 
Are there concerns that the 
index test or its 
interpretation differ from the 
review question? 
Are there concerns that the target 
condition as defined by the reference 
standard does not match the review 
question? 
- 
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